398491-59-3Relevant articles and documents
Dipeptidyl peptidase-IV inhibitor-aminotetrahydropyrane derivative
-
Paragraph 0103; 0104; 0105, (2017/07/23)
The invention provides a DPPIV inhibitor which has the structure shown as the formula (I) (please see the formula (I) in the description). Experiments show that the inhibitor can effectively inhibit the activity of dipeptidyl peptidase IV (DPPIV) and be used for preventing DPPIV-mediated diseases or delaying progress of the DPPIV-mediated diseases or treating the DPPIV-mediated diseases, particularly 2 type and 1 type diabetes, obesity, arthritis, osteoporosis and part of tumors. The invention further provides a preparation method of the inhibitor.
The discovery of novel 5,6,5- and 5,5,6-tricyclic pyrrolidines as potent and selective DPP-4 inhibitors
Cox, Jason M.,Chu, Hong D.,Kuethe, Jeffrey T.,Gao, Ying-Duo,Scapin, Giovanna,Eiermann, George,He, Huaibing,Li, Xiaohua,Lyons, Kathryn A.,Metzger, Joseph,Petrov, Aleksandr,Wu, Joseph K.,Xu, Shiyao,Sinha-Roy, Ranabir,Weber, Ann E.,Biftu, Tesfaye
, p. 2622 - 2626 (2016/05/09)
Novel potent and selective 5,6,5- and 5,5,6-tricyclic pyrrolidine dipeptidyl peptidase IV (DPP-4) inhibitors were identified. Structure-activity relationship (SAR) efforts focused on improving the intrinsic DPP-4 inhibition potency, increasing protease se
Structure-activity-relationship of amide and sulfonamide analogs of omarigliptin
Chen, Ping,Feng, Dennis,Qian, Xiaoxia,Apgar, James,Wilkening, Robert,Kuethe, Jeffrey T.,Gao, Ying-Duo,Scapin, Giovanna,Cox, Jason,Doss, George,Eiermann, George,He, Huaibing,Li, Xiaohua,Lyons, Kathryn A.,Metzger, Joseph,Petrov, Aleksandr,Wu, Joseph K.,Xu, Shiyao,Weber, Ann E.,Yan, Youwei,Roy, Ranabir Sinha,Biftu, Tesfaye
, p. 5767 - 5771 (2015/11/24)
A series of novel substituted-[(3R)-amino-2-(2,5-difluorophenyl)]tetrahydro-2H-pyran analogs have been prepared and evaluated as potent, selective and orally active DPP-4 inhibitors. These efforts lead to the discovery of a long acting DPP-4 inhibitor, omarigliptin (MK-3102), which recently completed phase III clinical development and has been approved in Japan.